Axonics Modulation Technologies Inc. (AXNX) Reports Q3 Loss of $2.67
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Axonics® Announces Third Quarter 2018 Financial Results and Operational Update
December 11, 2018 4:00 PM ESTIRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (SNM) devicesfor the treatment ofurinary and bowel dysfunction, reported today financial results for the quarter endedSeptember30, 2018 and provided an update on operational initiatives.
Recent Business Highlights
On November... More


